The purpose of this study was to evaluate the changes in physical performance under new treatment with SGLT2 inhibitors during in-patient rehabilitation over 28 days.

The study included 200 patients with type II diabetes mellitus which were divided in 2 groups of 100 patients: the first group was put under SGLT2 inhibitors and the second group had other diabetic regimen without SGLT2 inhibitors. The 6-minute walk test and the modified Borg scale (Range 0 - 10) were used to assess physical performance and the rate of dyspnea.

Compared to baseline, the change in the mean distance covered in the 6 minute walk test at 14 days in the SGLT2-inhibitor group was +70.1 ± 60.9 m vs. + 55.7 ± 64.8 m in the non SGLT2 inhibitor group; p=0.16. At 28 days, change in the first group was +104.5 ± 76.7 m vs. + 80.8 ± 82.9 m in the second group; p=0.03 (Figure 1) The mean modified BORG scale in the first group at baseline was 5.2 ± 2.3 and declined to 4.8 ± 2.1 at 14 days and further declined to 4.2 ± 2.4 at 28 days; p=0.007, whereas in the second group the BORG scale at baseline was 4.4 ± 2.4 and changed to 4.8 ± 2.2 at 14 days and remained unchanged at 4.8 ± 2.4 at 28 days; p=0.23

In conclusion, the introduction of an SGLT2-inhibitor was associated with a measurable improvement in physical performance and concomitant decline in the rate of perceived exertion within the first month despite having inadequate glycemic control at baseline.


M. Dumartin: None. D.S. Frundi: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at